SM2248
/ StarMab Biomed
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
Preclinical characterization of SM2248: A dual-action bispecific antibody enhancing immunotherapy for solid tumors
(AACR 2024)
- "SM2248, a humanized bispecific tetravalent VHH antibody targeting CD47 and CD40, exhibits promising in vivo efficacy and a favorable safety profile in preclinical studies, offering the potential for enhancing immunotherapy in solid tumors."
Preclinical • Oncology • Solid Tumor • CD40 • SIRPA
1 to 1
Of
1
Go to page
1